Remdesivir Alone or in Combination with Monoclonal Antibodies as an Early Treatment to Prevent Severe COVID-19 in Patients with Mild/Moderate Disease at High Risk of Progression: A Single Centre, Real-Life Study

Early treatment with antivirals against SARS-CoV-2 infection can prevent the onset of severe COVID-19 in fragile and immunocompromised patients. In this real-life, prospective, observational study, we evaluated efficacy and safety of a 3-day early treatment with remdesivir in adult and fragile patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Scotto, Riccardo, Buonomo, Antonio Riccardo, Iuliano, Antonio, Foggia, Maria, Sardanelli, Alessia, Villari, Riccardo, Pinchera, Biagio, Gentile, Ivan, Federico II COVID-Team
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/
https://www.ncbi.nlm.nih.gov/pubmed/36851078
http://dx.doi.org/10.3390/vaccines11020200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964994/
https://www.ncbi.nlm.nih.gov/pubmed/36851078
http://dx.doi.org/10.3390/vaccines11020200

Ejemplares similares